Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer

Cancer Science

Volumn 102, Issue 11, 2011, Pages 1977-1990

  Fujie, Hitomi ^a   Tanaka, Toshiaki ^b   Tagawa, Masatoshi ^c   Kaijun, Niu ^d   Watanabe, Mika ^e   Suzuki, Takashi ^f   Nakayama, Katsutoshi ^g   Numasaki, Muneo ^a  

^a JOSAI UNIVERSITY   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c CHIBA CANCER CENTER   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY HOSPITAL   (Japan)

^f TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR 1; INTERFERON RECEPTOR; INTERLEUKIN 28; INTERLEUKIN 29; KI 67 ANTIGEN; PROTEIN P21; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, SCID; NEOPLASM PROTEINS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, CYTOKINE; TUMOR STEM CELL ASSAY; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054982461     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02079.x     Document Type: Article

References (48)

1. Vilcek J. Novel interferons. Nat Immunol 2003; 4: 8-9.
2. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
3. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
4. Leaman DW. Mechanism of interferon action. Prog Mol Subcell Biol 1998; 20: 101-42.
5. Pfeffer LM, Dinarello CA, Herberman RB et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489-99.
6. Weiss K. Safety profile of interferon-α therapy. Semin Oncol 1998; 25: 9-13.
7. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005; 31: 109-18.
8. Brand S, Beigel F, Olszak T et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: G960-8.
9. Zitzmann K, Brand S, Baehs S et al. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344: 1334-41.
10. Li Q, Kawamura K, Ma G et al. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 2010; 46: 180-90.
11. Guenterberg KD, Grignol VP, Raig ET et al. Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther 2010; 9: 510-20.
12. Maher SG, Sheikh F, Scarzello AJ et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-15.
13. Steen HC, Gamero AM. Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 2010; 30: 597-602.
14. Lasfar A, Lewis-Antes A, Smirnov SV et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66: 4468-77.
15. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006; 176: 7686-94.
16. Numasaki M, Tagawa M, Iwata F et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178: 5086-98.
17. Abushahba W, Balan M, Castaneda I et al. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010; 59: 1059-71.
18. Numasaki M, Watanabe M, Suzuki T et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175: 6177-89.
19. Fujiwara H, Yamakuni T, Ueno M et al. IC101 induces apoptosis by Akt dephosphorylation via an inhibition of heat shock protein 90-ATP binding activity accompanied by preventing the interaction with Akt in L1210 cells. J Pharmacol Exp Ther 2004; 310: 1288-95.
20. Horton HM, Hernandez P, Parker SE, Barnhart KM. Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice. Cancer Res 1999; 59: 4064-8.
21. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Takeda K. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 2000; 45: 199-206.
22. Nakayama K, Pergolizzi RG, Crystal RG. Gene transfer-mediated pre-mRNA segmental trans-splicing as a strategy to deliver intracellular toxins for cancer therapy. Cancer Res 2004; 65: 254-63.
23. 2 phase with accumulation of mitotic cyclins. J Virol 2001; 75: 7555-63.
24. Numasaki M, Fukushi J, Ono M et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-7.
25. Rysiecki G, Gewert DR, Williams BR. Constitutive expression of a 2', 5'-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression. J Interferon Res 1989; 9: 649-57.
26. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N. Malignant transformation by a mutation of the IFN-inducible dsRNA-dependent protein kinase. Science 1992; 257: 1685-9.
27. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 1993; 12: 3297-304.
28. Clemens MJ. PKR-α protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol 1997; 29: 945-9.
29. Basile JR, Eichten A, Zacny V, Munger K. NF-kappa B-mediated induction of p21(Cip1/Waf1) by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol Cancer Res 2003; 1: 262-70.
30. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996; 271: 499-502.
31. Bates S, Ryan KM, Phillips AC, Vousden KH. Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. Oncogene 1998; 17: 1691-703.
32. Tsukada Y, Tanaka T, Miyazawa K, Kitamura N. Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2. J Biochem 2004; 136: 701-9.
33. Hall MC, Li Y, Pong RC, Ely B, Sagalowsky AI, Hsieh JT. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. J Urol 2000; 163: 1033-8.
34. Harada K, Kurisu K, Sadatomo T et al. Growth inhibition of human glioma cells by transfection-induced p21 and its effects on telomerase activity. J Neurooncol 2000; 47: 39-46.
35. Waf1/Cip1 in NIH3T3 cell line. Cell Res 2002; 12: 229-33.
36. Sangfelt O, Erickson S, Castro J et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999; 18: 2798-810.
37. Han J, Tsukada Y, Hara E, Kitamura N, Tanaka T. Hepatocyte growth factor induces redistribution of p21CIP1 and p27KIP1 through ERK-dependent p16INK4a up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem 2005; 280: 31548-56.
38. Vonlanthen S, Heighway J, Tschan MP et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998; 17: 2779-85.
39. Kratzke RA, Greatens TM, Rubins JB et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996; 56: 3415-20.
40. Taga S, Osaki T, Ohgami A et al. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. Cancer 1997; 80: 389-95.
41. Sangfelt O, Erickson S, Einhorn S, Grander D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 1997; 14: 415-33.
42. Tada S, Saito H, Tsunematsu S et al. Interferon regulatory factor-1 gene abnormality and loss of growth inhibitory effect of interferon-alpha in human hepatoma cell lines. Int J Oncol 1998; 13: 1207-16.
43. Moro A, Calixto A, Suarez E, Arana MJ, Perea SE. Differential expression of the p27Kip1 mRNA in IFN-sensitive and resistant cell lines. Biochem Biophys Res Commun 1998; 245: 752-6.
44. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155-61.
45. Komiya T, Hosono Y, Hirashima T et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997; 3: 1831-5.
46. Shoji T, Tanaka F, Takata T et al. Clinical significance of p21 expression in non-small cell lung cancer. J Clin Oncol 2002; 20: 3865-71.
47. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11: 3974-86.
48. Liu BS, Janssen HL, Boonstra A. IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expression. Blood 2011; 117: 2385-95.